News Content
### Onset of Action and Core Treatment Cycle The blood glucose lowering effect is usually rapid; most patients can observe a decrease in glycated hemoglobin within 1-4 weeks of medication. Oral formulations such as Orforglipron reach peak plasma concentration 2-4 hours after administration, and daily dosing can quickly stabilize blood glucose. Weight loss requires a longer period; significant weight loss usually appears after 8-12 weeks of medication. In some potent formulations, such as retaglutide, a phase III trial showed an average weight loss of 28.7% over 68 weeks. In clinical practice, the core treatment phase typically lasts 3-6 months, during which the dosage is gradually adjusted to achieve the blood glucose or weight control target.https://www.fiercerawsource.com/peptides/premium-high-purity-peptides-glp-1.html
### Individualized Adjustment of Maintenance Cycle After achieving the treatment goal, the maintenance phase begins, and the dosing frequency can be flexibly optimized. A 2025 study by the American Obesity Association showed that patients with normalized weight could reduce dosing from once a week to once every two weeks, with 26/30 patients successfully maintaining their weight loss, and body fat percentage and metabolic indicators continuing to improve. Patients with cardiovascular risk or kidney disease require long-term maintenance therapy to obtain cardio- and renal protective benefits; the maintenance course for some weekly formulations, such as semaglutide, can be extended to more than one year.
### Key Warnings for Cycle Management Repeated discontinuation of medication can lead to metabolic deterioration. Animal studies have confirmed that intermittent use of GLP-1 drugs can lead to weight rebound, lean body mass loss, and increased insulin resistance. Experts emphasize that cycle adjustments must be made under the guidance of a physician and should not be interrupted on one's own. Dietary and exercise interventions should also be implemented to avoid rebound effects caused by relying solely on medication.
With formulation innovation and optimized individualized regimens, GLP-1 treatment is shifting from fixed-course treatment to "goal-oriented cycle management," balancing efficacy and patient adherence.
